BIOPTIC® AI agents triage, assess, and prioritize drug assets worldwide, fusing molecular insight, clinical evidence, and deal economics into a single AI-driven decision engine.
Automate pipeline development. Surface undervalued assets in any language. Scale scientific and business diligence 103×.
Integrated AI Agents
Asset Scouting
Scans every paper, filing and news source in every language worldwide to surface and cluster deal opportunities.
In-Licensing
Ranks best‑fit external assets, drafts term sheets and automates outreach.
Due Diligence
Assembles red‑flag memos from
trial data, patents, and competitive
intel in hours
Commercialization
Sizes markets, models pricing & access, builds launch scenarios.
Proprietary Scientific Models
B1
B2
B3
Platform
Precision search
Pinpoint by indication, target, modality or molecule with clean, fully referenced results
Zero hallucinations
Benchmark-proven multi-agent QA with in-house checks, citations, and numeric plot audits
Curated data stack
Only high-quality, licensed sources: SEC filings, FDA guidelines, trials, market and media feeds
Reinforcement loop
Continuous improvement through regular RLHF retraining that incorporates user queries and human feedback
Autonomous monitoring
Agents track trials, patents, licensing deals, and regulatory shifts in real time
Venture creation firm that builds and funds a new generation of biotechnology companies.
"Our early work with OPTIC’s B1 and B2 models showed real promise in integrating AI into drug discovery. We look forward to seeing how the BIOPTIC agentic AI platform will further connect our scientific discoveries to strategic business insights, providing a powerful edge in our venture creation strategy"
— James Sietstra, Founder and General Partner at Mechanica Partners
Reqest a demo
Schedule a 30 minute demo to see BIOPTIC® AI agents surface qualified assets for your focus area.
Founded by former Google executives, our team unites AI researchers, life scientists, and biopharma strategy experts with backgrounds across pharma, tech, academia and consulting
© Optic, Inc. All rights reserved.